Nano-silver nitrate
PreclinicalSmall molecule
Nano-silver nitrate is one of 16 small molecule programs targeting Emphysema. It is currently in Preclinical.
1
Indications
1
Total Trials
1
Active Trials
15
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
16 competitors in Emphysema
#DrugCompanyPhaseTrials
1Viagra
VViatris Specialty LLC
Approved
Serevent
GGlaxo Dba Glaxosmithkline
Approved
Pulmicort
SSalix
Approved
Advil
KKenvue Brands
Approved
Foradil
ViatrisApproved
Vibramycin
PPfizer's Upjohn has merged with Mylan to form Viatris Inc.
Phase 2
Veramyst
GSKPreclinical
Spiriva
Boehringer IngelheimPreclinical
Spiriva
Boehringer IngelheimPreclinical
Atrovent
Boehringer IngelheimPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Nano-silver nitrate. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company
- MMansoura University Hospital